Hyperthermia: Uncoupling the agony from Ecstasy

Information

  • Research Project
  • 7299087
  • ApplicationId
    7299087
  • Core Project Number
    R15DA022712
  • Full Project Number
    1R15DA022712-01A1
  • Serial Number
    22712
  • FOA Number
    PA-06-42
  • Sub Project Id
  • Project Start Date
    8/1/2007 - 17 years ago
  • Project End Date
    7/31/2010 - 14 years ago
  • Program Officer Name
    FRANKENHEIM, JERRY
  • Budget Start Date
    8/1/2007 - 17 years ago
  • Budget End Date
    7/31/2010 - 14 years ago
  • Fiscal Year
    2007
  • Support Year
    1
  • Suffix
    A1
  • Award Notice Date
    7/23/2007 - 17 years ago
Organizations

Hyperthermia: Uncoupling the agony from Ecstasy

[unreadable] DESCRIPTION (provided by applicant): The hyperthermia induced by sympathomimetic agents such as Ecstasy (3,4- methylenedioxymethamphetamine, MDMA) is the most acute life-threatening consequence associated with their use. With the ever-increasing popularity of Ecstasy among today's youth, the elucidation of the mechanisms by which this hyperthermia occurs is crucial to developing optimal treatments. The overall HYPOTHESIS to be evaluated is that temporal increases in plasma free fatty acids (FFAs), norepinephrine (NE) and epinephrine (Epi) contribute to the activation of skeletal muscle uncoupling protein 3 (UCP3) and produce a thermogenic crisis following exposure to Ecstasy. Specific Aims: (1) Characterize plasma changes in FFAs, NE and Epi during the heat generation phase (0 to 60 minutes post-treatment) of Ecstasy exposure. These changes in plasma levels will then be correlated to the thermogenic effects of Ecstasy. (2) Define the intracellular transduction mechanisms which mediate UCP3-dependent hyperthermia as a consequence of Ecstasy use. These studies will be performed in both in vivo and in vitro models in order to obtain a thorough understanding of the cellular mechanisms involved in Ecstasy-induced thermogenesis. Significance. These studies will provide insight into the cellular mechanisms vital to the hyperthermia initiated by both Ecstasy and other sympathomimetic agents. Furthermore, defining the mechanisms of UCP3 activation will lead to improved targeted therapies for treatment of heat-related illnesses such as pheochromocytoma and hyperthyroidism. Over the past decade, the number of emergency room visits associated with stimulant abuse such as Ecstasy and methamphetamine has dramatically increased. One of the most acute life-threatening consequences of these agents is hyperthermia. This proposal will examine the factors that contribute to the development of this hyperthermia. The research proposed in this application is significant, because understanding the mechanism underlying Ecstasy-induced hyperthermia will provide a basis for the development of treatments for hyperthermia not only from Ecstasy and other sympatho- mimetic agents (methamphetamine) but also for other heat-related illnesses (eg. thyrotoxic [unreadable] crisis). [unreadable] [unreadable] [unreadable]

IC Name
NATIONAL INSTITUTE ON DRUG ABUSE
  • Activity
    R15
  • Administering IC
    DA
  • Application Type
    1
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    247500
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    279
  • Ed Inst. Type
    SCHOOLS OF PHARMACY
  • Funding ICs
    NIDA:247500\
  • Funding Mechanism
  • Study Section
    IPOD
  • Study Section Name
    Integrative Physiology of Obesity and Diabetes Study Section
  • Organization Name
    OHIO NORTHERN UNIVERSITY
  • Organization Department
    NONE
  • Organization DUNS
  • Organization City
    ADA
  • Organization State
    OH
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    45810
  • Organization District
    UNITED STATES